We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Spruce Biosciences Inc
9 own
14 watching
Current Price
$0.41
$0
(0.2%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
18.59M
52-Week High
5.95000
52-Week Low
0.34200001
Average Volume
0.79M
Dividend Yield
--
P/E Ratio
--
Market Capitalization18.59M52-Week High5.9500052-Week Low0.34200001Average Volume0.79MDividend Yield--P/E Ratio--What does the Spruce Biosciences Inc do?
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.
Read More
How much money does Spruce Biosciences Inc make?
News & Events about Spruce Biosciences Inc.
PR Newswire
2years ago
Thinking about buying stock in SWVL Holdings, Apexigen, Sonnet BioTherapeutics, Spruce Biosciences, or Tilray? Thinking about buying stock in SWVL Holdings, Apexigen, Sonnet BioTherapeutics, Spruce Biosciences, or Tilray? PR Newswire NEW YORK, Jan. 9, 2023 NEW YORK, Jan. 9, 2023 /PRNewswire...
Pharmaceutical Business Review
2years ago
As per the terms of the agreement, Spruce will get an upfront payment of $15m from Kaken. It will also be eligible to get further payments following the
The post Spruce Biosciences, Kaken Pharmaceutical sign deal for tildacerfont to treat CAH appeared first on Pharmaceutical Business review...
Benzinga
2years ago
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
read more...
PR Newswire
2years ago
Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? PR Newswire NEW YORK, Jan. 6, 2023 NEW...
Ticker Report
2years ago
Relmada Therapeutics (NASDAQ:RLMD Get Rating) and Spruce Biosciences (NASDAQ:SPRB Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, ...
Frequently Asked Questions
Frequently Asked Questions
What is Spruce Biosciences Inc share price today?
Can Indians buy Spruce Biosciences Inc shares?
How can I buy Spruce Biosciences Inc shares from India?
Can Fractional shares of Spruce Biosciences Inc be purchased?
What are the documents required to start investing in Spruce Biosciences Inc stocks?
What is today’s traded volume of Spruce Biosciences Inc?
What is today’s market capitalisation of Spruce Biosciences Inc?
What is the 52-Week High and Low Range of Spruce Biosciences Inc?
What percentage is Spruce Biosciences Inc down from its 52-Week High?
What percentage is Spruce Biosciences Inc up from its 52-Week Low?
Current Price
$0.41
$0
(0.2%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.